Cardiovascular health and diabetes

Module 6: Cardiovascular disease — the Steno-2 trial

Please log in to access the chapters in this module.
CME Credits: 1
Module duration: 1 hour
Launch date: Spring 2020 (version 1)
Updated: Autumn 2022 (version 2)
Expiry date: March 2027
Audience: Cardiologists (Subspeciality), Diabetes and Metabolism Specialists (Subspeciality), Endocrinologists (Subspeciality), General Physicians (Subspeciality), Public Health Physicians (Subspeciality)

My name is Miles Fisher. I’m a Clinical Diabetologist at Glasgow Royal Infirmary and an Honorary Professor at the University of Glasgow. I’m here today with Peter Gaede, who was one of the principal investigators on the Steno-2 trial.

Learning Outcomes

By the end of this module, you will be able to:

Explain the study design, treatment goals and the primary and secondary outcomes of the original Steno-2 trial

Summarise the relative and absolute risk reductions for micro- and macrovascular complications, and the effect of early intervention strategies, like that of the Steno-2 trial, on mortality and life expectancy

Develop management plans for people with diabetes based on the evidence from the Steno-2 trial


This module includes self-marked assessments, such as knowledge checks and/or case studies, as well as a marked final assessment, which you can attempt up to five times. To complete the module, you must review all chapters, pass the final assessment (80% pass mark), and fill in our feedback form.


Contributors

Professor
Miles Fisher
Author
Professor
Peter Gaede
Author
Professor
John Wilding
Expert Reviewer
Assessment Setter
Assessment Setter
Assessment Setter